

Nathan Peiffer-Smadja

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7739180/publications.pdf>

Version: 2024-02-01

47
papers

2,821
citations

430442

18
h-index

197535

49
g-index

69
all docs

69
docs citations

69
times ranked

4460
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	2.8	569
2	Type 1 interferons as a potential treatment against COVID-19. <i>Antiviral Research</i> , 2020, 178, 104791.	1.9	425
3	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 209-221.	4.6	233
4	Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2021, 27, 19-27.	2.8	230
5	Machine learning for clinical decision support in infectious diseases: a narrative review of current applications. <i>Clinical Microbiology and Infection</i> , 2020, 26, 584-595.	2.8	218
6	Open science saves lives: lessons from the COVID-19 pandemic. <i>BMC Medical Research Methodology</i> , 2021, 21, 117.	1.4	122
7	Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies. <i>BMJ Open</i> , 2021, 11, e052777.	0.8	114
8	Neurologic manifestations associated with COVID-19: a multicentre registry. <i>Clinical Microbiology and Infection</i> , 2021, 27, 458-466.	2.8	95
9	Omicron SARS-CoV-2 variant: What we know and what we don't. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2022, 41, 100998.	0.6	93
10	An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- β -1a and hydroxychloroquine in hospitalized patients with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1826-1837.	2.8	77
11	Assessment of Air Contamination by SARS-CoV-2 in Hospital Settings. <i>JAMA Network Open</i> , 2020, 3, e2033232.	2.8	76
12	Performance and impact of a multiplex PCR in ICU patients with ventilator-associated pneumonia or ventilated hospital-acquired pneumonia. <i>Critical Care</i> , 2020, 24, 366.	2.5	62
13	Machine Learning for COVID-19 needs global collaboration and data-sharing. <i>Nature Machine Intelligence</i> , 2020, 2, 293-294.	8.3	48
14	Learning from public health and hospital resilience to the SARS-CoV-2 pandemic: protocol for a multiple case study (Brazil, Canada, China, France, Japan, and Mali). <i>Health Research Policy and Systems</i> , 2021, 19, 76.	1.1	33
15	Nebulised interferon beta-1a for patients with COVID-19. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 122-123.	5.2	32
16	The cerebral bases of the bouba-kiki effect. <i>NeuroImage</i> , 2019, 186, 679-689.	2.1	27
17	Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2376-2380.	1.3	25
18	Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1404-1412.	1.3	25

#	ARTICLE	IF	CITATIONS
19	Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial). <i>Trials</i> , 2020, 21, 846.	0.7	21
20	Hydroxychloroquine and COVID-19: a tale of populism and obscurantism. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e121.	4.6	17
21	COVID-19 vaccine boosters: What do we know so far?. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100959.	0.6	17
22	The challenge of implementing Less is More medicine: A European perspective. <i>European Journal of Internal Medicine</i> , 2020, 76, 1-7.	1.0	15
23	Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response. <i>Clinical Microbiology and Infection</i> , 2021, 27, 138-140.	2.8	15
24	Added value of rapid respiratory syndromic testing at point of care versus central laboratory testing: a controlled clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, iii20-iii27.	1.3	14
25	Paving the Way for the Implementation of a Decision Support System for Antibiotic Prescribing in Primary Care in West Africa: Preimplementation and Co-Design Workshop With Physicians. <i>Journal of Medical Internet Research</i> , 2020, 22, e17940.	2.1	14
26	Re: effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: author's response. <i>Clinical Microbiology and Infection</i> , 2021, 27, 920-921.	2.8	13
27	Corticosteroids and immunosuppressive agents for idiopathic recurrent pericarditis. <i>Autoimmunity Reviews</i> , 2019, 18, 621-626.	2.5	12
28	In vitro bactericidal activity of amoxicillin combined with different cephalosporins against endocarditis-associated <i>Enterococcus faecalis</i> clinical isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3511-3514.	1.3	11
29	COVID-19 vaccines: A race against time. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100848.	0.6	11
30	Vaccination and blood sampling acceptability during Ramadan fasting month: A cross-sectional study in Conakry, Guinea. <i>Vaccine</i> , 2017, 35, 2569-2574.	1.7	10
31	Tocilizumab-Induced Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in Adult-Onset Still Disease. <i>Annals of Internal Medicine</i> , 2017, 167, 141.	2.0	9
32	Anticovid, a comprehensive open-access real-time platform of registered clinical studies for COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2708-2710.	1.3	8
33	How and why do French medical students choose the specialty of infectious and tropical diseases? A national cross-sectional study. <i>BMC Medical Education</i> , 2020, 20, 397.	1.0	8
34	Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 764-765.	4.6	8
35	Re: "Determinants of in-hospital antibiotic prescription behaviour"™ by Lambregts et al.. <i>Clinical Microbiology and Infection</i> , 2019, 25, 635-637.	2.8	7
36	A computerized decision support system (CDSS) for antibiotic prescription in primary care" Antibiotic: implementation, adoption and sustainable use in the era of extended antimicrobial resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2353-2362.	1.3	7

#	ARTICLE	IF	CITATIONS
37	High-dose daptomycin in patients with infective endocarditis or sternal wound infections. <i>Clinical Microbiology and Infection</i> , 2018, 24, 1106-1108.	2.8	6
38	Aims and challenges of building national trainee networks in clinical microbiology and infectious disease disciplines. <i>Future Microbiology</i> , 2021, 16, 687-695.	1.0	6
39	The French Society of Internal Medicine's Top-5 List of Recommendations: a National Web-Based Survey. <i>Journal of General Internal Medicine</i> , 2019, 34, 1475-1485.	1.3	5
40	Clinical Decision Support Systems for Antibiotic Prescribing: An Inventory of Current French Language Tools. <i>Antibiotics</i> , 2022, 11, 384.	1.5	5
41	Ecological Momentary Assessment Using Smartphones in Patients With Depression: Feasibility Study. <i>JMIR Formative Research</i> , 2021, 5, e14179.	0.7	4
42	A case of thoracic actinomycosis presenting as sudden paraplegia. <i>Revue Neurologique</i> , 2019, 175, 89-92.	0.6	3
43	Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial's authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 277-279.	1.3	2
44	Role and perception of clinical microbiology and infectious diseases trainees during the COVID-19 crisis. <i>Future Microbiology</i> , 2022, 17, 411-416.	1.0	2
45	Une langue qui parle d'elle-même. <i>Pratique Neurologique - FMC</i> , 2017, 8, 183-184.	0.1	1
46	Cultural Differences Between Surgical and Medical Teams: Is it Time for Comanagement?. <i>Clinical Infectious Diseases</i> , 2019, 69, 560-561.	2.9	1
47	The role of infectious disease trainees during the first wave of the COVID-19 pandemic: A national survey. <i>Infectious Diseases Now</i> , 2021, 51, 215-217.	0.7	1